Home : FDA Drug Database : Asmanex Twisthaler : MSN Newsfeeds
Asmanex Twisthaler - MSN Newsfeeds
- HealthCentral.com - Mometasone furoate monohydrate, the active component of NASONEX Nasal Spray, 50 mcg, is an anti-inflammatory corticosteroid having the chemical name, 9,21-Dichloro-11, 17-dihydroxy-16 -methylpregna-1,4-diene-3,20-dione 17-( 2 furoate) monohydrate ...
- Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 2007;30:317-326. Abstract Meltzer EO. Intranasal steroids: managing allergic rhinitis and tailoring treatment to patient preference ...
- Schering-Plough Corporation, (NYSE: SGP ) announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and ...
- The European regulatory agency will review a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older. The Food and Drug Administration is also currently ...
- About the Investigational Mometasone Furoate and Formoterol Fumarate Combination Schering-Plough has exclusive worldwide rights for the development and commercialization of the mometasone furoate and formoterol fumarate fixed-dose combination. In the ...
- Schering-Plough Corp. said Wednesday the European Medicines Agency is reviewing marketing applications for an asthma treatment and an oral contraceptive. The European regulatory agency will review a fixed-dose combination of mometasone furoate and ...
- ASMANEX TWISTHALER (mometasone furoate inhalation powder) is approved in the U.S. for the maintenance treatment of asthma in patients 4 years of age and older. ASMANEX TWISTHALER will not relieve sudden asthma symptoms and is not for children under ...
- ASMANEX TWISTHALER will not relieve sudden asthma symptoms and is not for children under the age of 4. ASMANEX TWISTHALER is available in two dose strengths in the U.S., 110 mcg for children between 4 and 11 years old, and 220 mcg for patients 12 and ...
- By Margarita Snegireva. The Food and Drug Administration has approved new inhaled steroid treatment for preventing asthma attacks in young children produced by Schering -Plough Corp. Its Asmanex Twisthaler is the first once-a-day, inhaled ...
- Inhaler may now be used by kids as young as 4 years TUESDAY, Feb. 5 (HealthDay News) -- Schering-Plough's Asmanex Twisthaler, an inhaled steroid designed to prevent asthma attacks, has been approved by the U.S. Food and Drug Administration for ...






